EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.

doi:10.1007/s00432-013-1454-9

Article

EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.

Journal of cancer research and clinical oncology - 1 Aug 2013

Ito Yuriko, Yamada Yasuhide, Asada Kiyoshi, Ushijima Toshikazu, Iwasa Satoru, Kato Ken, Hamaguchi Tetsuya, Shimada Yasuhiro

Abstract excerpt

BACKGROUND: The KRAS mutation has been associated with resistance to cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in metastatic colorectal cancer (mCRC). However, the predictive biomarkers of cetuximab resistance in KRAS wild-type mCRC remain unknown except BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.

Abstract excerpt

Topics

Related research